(UroToday.com) It is well known that inflammation is a hallmark of cancer, harboring a critical role in tumor development and metastatic progression in many cancers, including prostate cancer.1 It has been shown that baseline neutrophil-to-lymphocyte ratio (NLR), calculated by dividing the absolute peripheral neutrophil count by the absolute lymphocyte count, is an accessible and inexpensive marker of cancer inflammation.2 When this ratio is high at baseline, data shows its associated with poor overall survival (OS) in many tumor types, including metastatic castration-resistant prostate cancer (mCRPC).2